Jupiter Neurosciences, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report (Form 8-K) was filed by Jupiter Neurosciences, Inc. (Nasdaq: JUNS) on June 2, 2026. The report details compensatory arrangements entered into during the period, specifically focusing on executive employment amendments and equity grants approved by the Board of Directors and the Compensation Committee.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The document focuses exclusively on executive compensation and equity grants.
Material Changes and Executive Compensation
On June 2, 2026, the Company approved significant changes to executive and director compensation under the Jupiter Neurosciences, Inc. 2025 Equity Incentive Plan:
- Alison Silva (COO and President): Her employment agreement was amended to increase her base salary from $315,000 to $340,200. Additionally, she received a one-time grant of options to purchase 600,000 shares.
- Executive Discretionary Bonus Options: The Board approved stock option grants in lieu of cash bonuses for the following executives:
| Executive | Title | Option Grant |
|---|---|---|
| Christer Rosén | Chairman, CEO, Director | 747,783 |
| Alison Silva | COO, President | 427,304 |
| Saleem Elmasri | CFO | 325,565 |
| Marshall Hayward, Ph.D. | CSO, Director | 259,231 |
| Alexander Rosén | CAO | 341,843 |
Additional Grants: Saleem Elmasri (CFO) received an additional one-time grant of 200,000 options to recognize his contributions. Independent non-employee directors each received a grant of 100,000 options.
All option grants have an exercise price equal to the closing price of the Company's common stock on the date of grant. Vesting occurs over three years in equal quarterly installments, commencing September 2, 2026, subject to continued service.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, operational outlook, or specific risk factors beyond the standard vesting conditions tied to continued service.
Key Facts for Investor Verification
- Verify the total number of shares authorized under the 2025 Equity Incentive Plan to assess the dilution impact of the approximately 3.2 million options granted in this filing.
- Confirm the closing stock price on June 2, 2026, to determine the exercise price for the new grants.
- Review the full text of Amendment No. 3 to Alison Silva's employment agreement (Exhibit 10.1) for additional terms not summarized in the 8-K.
- Monitor the Company's cash burn rate, as these grants were issued in lieu of cash bonuses, potentially preserving liquidity.